Tim Kutzkey Buys 15,100 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 15,100 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were acquired at an average price of $19.89 per share, with a total value of $300,339.00. Following the purchase, the director owned 989,893 shares of the company’s stock, valued at $19,688,971.77. The trade was a 1.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Tim Kutzkey also recently made the following trade(s):

• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The stock was bought at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Trading Down 4.6%

Shares of NASDAQ SRZN traded down $0.91 during mid-day trading on Thursday, reaching $19.06. The company had a trading volume of 14,409 shares, compared to its average volume of 76,400. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94. The stock has a market cap of $163.34 million, a P/E ratio of -0.85 and a beta of 0.58. The firm has a 50 day simple moving average of $17.88 and a two-hundred day simple moving average of $13.47.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The firm had revenue of $0.98 million for the quarter. On average, equities analysts expect that Surrozen, Inc. will post -8.49 EPS for the current year.

Hedge Funds Weigh In On Surrozen

A number of large investors have recently modified their holdings of SRZN. Stempoint Capital LP boosted its stake in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after acquiring an additional 20,247 shares during the period. Vanguard Group Inc. boosted its position in shares of Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Acuta Capital Partners LLC grew its stake in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares during the period. Finally, Braidwell LP purchased a new position in shares of Surrozen in the 2nd quarter valued at about $1,252,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SRZN has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Surrozen currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.